Abstract:Potential conflict of interest: Nothing to report. This work is supported by the National Natural Science Foundation of China (grant 81902379) and the Cultivation Foundation of Renji Hospital (grant PY2018‐III‐01). To the Editor: We read with great interest the recent article by De Martin et al.(1) regarding the analysis of liver transplantation (LT) versus liver resection (LR) for patients with cirrhosis with small intrahepatic cholangiocarcinoma (iCCA) and combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA). The authors retrospectively evaluated a total of 75 patients with cirrhosis who were confirmed iCCA/cHCC‐CCA ≤5 cm and compared them by different operation types of LT or LR. Surprisingly, 49 LT patients had a significantly better 5‐year recurrence‐free survival compared with patients in the LR group (75% versus 36%; P = 0.004). The overall survival was also comparable between 2 groups. The results are encouraging for patients suffering iCCA/cHCC‐CCA with limited therapies, and the findings may suggest an expansion of the criteria of LT. The authors also analyzed a subgroup of patients with tumors >2 cm but <5 cm. Consistent with previous results, a favorable outcome was also confirmed in LT patients with a 5‐year recurrence‐free survival of 74%. In addition, tumor differentiation was found to be independently associated with tumor recurrence. On the basis of these findings, the authors concluded that LT could provide a better strategy for patients with cirrhosis with iCCA/cHCC‐CCA <5 cm. We appreciate the well‐designed research that evaluates LT for cholangiocarcinoma. However, certain points need to be further discussed when interpreting the results. First of all, transarterial chemoembolization (TACE) for liver tumors has been acknowledged as one of the locoregional treatments that inhibits active tumor cells, induces tumor necrosis, and reduces vascular metastasis.(2) However, a significantly higher rate of preoperative TACE treatment was found in the LT group (P = 0.005). This may provide potential benefits for LT patients in evaluating posttransplant outcomes. Second, there is increasing evidence showing that the biological stability of a tumor appears to be more important for prognosis than tumor size and number. Lunsford et al.(3) reported that patients with iCCA who showed tumor stability on preoperative neoadjuvant therapy benefited from LT. In the present study, a longer interval was revealed between tumor diagnosis and operation in patients receiving LT. However, neither tumor growth nor falling outside the French alpha‐fetoprotein criteria was reported in these patients, who demonstrated tumor stability rather than tumor category as defined only by tumor size. This subgroup of patients should be further evaluated in detail. Another important issue is related to lymph node status, which is an important factor impacting patient survival after operation for cholangiocarcinoma.(4) The absence of lymph node metastasis has been listed as one of the standards for LT in hilar cholangiocarcinoma.(5) However, because of a lack of diagnosis of iCCA/cHCC‐CCA before transplant, the authors did not routinely perform lymphadenectomy in the present study. Therefore, future studies should include lymph node dissection during LT to confirm whether positive nodes affect the prognosis in LT for small iCCA/cHCC‐CCA. In conclusion, the recommendation of LT for patients with cirrhosis with iCCA/cHCC‐CCA <5 cm needs further exploration in larger, prospective studies with careful evaluation in tumor biological stability and lymph node status. We believe that in selected patients with iCCA/cHCC‐CCA, LT could provide a favorable prognosis.

The Outcome of Liver Transplantation for 12 Patients with Cholangiocellular Carcinoma

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Liver transplantation for cholangiocarcinoma in 6 patients

[Influence of Tumor Characteristics on the Outcome of Liver Transplantation among Patients with Hepatocellular Carcinoma].

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular‐Cholangiocarcinoma in the Setting of Cirrhosis

The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Analysis of survival and prognostic factors of liver transplantation for hepatocellular carcinoma

Liver Transplantation for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Analysis

Liver Transplantation for Patients with Hepatocellular Carcinoma at the Liver Cancer Institute of Fudan University, China.

Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database

Clinical Analysis of 67 Cases of Liver Transplantation for Hepatocellular Carcinoma

Efficacy of Liver Transplantation for Hepatic Andhilar Cholangiocarcinoma

Expanded Criterion for Hepatocellular Carcinoma in Liver Transplantation

Liver transplantation for 23 patients with hepatocellular carcinoma

Analysis of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Recurrence Following Liver Transplantation.

Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation

OUTCOME OF HEPATIC RESTION FOR SINGLE LARGE HEPATOCELLULAR CARCINOMA (HCC) MORE THAN10CM IN DIAMETER